Analyst Price Targets — AVTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 8:38 pm | — | Wolfe Research | $48.00 | $14.41 | TheFly | Avalo Therapeutics initiated with an Outperform at Wolfe Research |
| February 2, 2026 11:10 am | — | Guggenheim | $50.00 | $15.11 | TheFly | Avalo Therapeutics initiated with a Buy at Guggenheim |
| December 17, 2025 9:14 pm | Joseph Catanzaro | Mizuho Securities | $39.00 | $19.25 | TheFly | Avalo Therapeutics initiated with an Outperform at Mizuho |
| September 17, 2025 3:35 pm | — | H.C. Wainwright | $25.00 | $11.33 | TheFly | Avalo Therapeutics price target raised to $25 from $15 at H.C. Wainwright |
| March 25, 2025 8:49 am | Kambiz Yazdi | Jefferies | $23.00 | $8.54 | TheFly | Avalo Therapeutics initiated with a Buy at Jefferies |
| April 16, 2024 6:50 am | Leland Gershell | Oppenheimer | $35.00 | $15.24 | StreetInsider | Oppenheimer Upgrades Avalo Therapeutics (AVTX) to Outperform following AVTX-009 acquisition |
Latest News for AVTX
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced the pricing of its underwritten public offering of 19,730,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase…
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase…
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced positive topline results from its Phase 2 LOTUS trial evaluating the efficacy and safety of abdakibart in adults with moderate to severe hidradenitis suppurativa (HS). The LOTUS…
WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced that it has entered into a Milestone Buyout Option and Amendment Agreement (the “Buyout Agreement”) related to the company's prior acquisition of AlmataBio, Inc. in March…
Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AVTX.
U.S. House Trading
No House trades found for AVTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.